Table 3.

Study withdrawals and reasons (intention-to-treat population)

			Artesunate–mefloquine (n=472)	Artemether–lumefantrine (n=472)
Completed study			204 (43·2%)	202 (42·8%)
Withdrawal from study			268 (56·8%)	270 (57·2%)
Reasons for withdrawal*
	Early treatment failure
		Parasitaemia with sign/danger of severe malaria on days 0, 1, or 2	2 (0·7%)	0
		Higher parasitaemia on day 2 than day 0	0	0
		Parasitaemia on day 3 with axillary temperature of ≥37·5°C	0	0
		Parasitaemia count on day 3 ≥25% than on day 0	0	0
	Late treatment failure
		Late clinical failure	61 (22·8%)	69 (25·6%)
		Late parasitological failure	153 (57·1%)	142 (52·6%)
	Adverse event		8 (3·0%)	4 (1·5%)
	Serious adverse event		0	2 (0·7%)
	Parent or guardian's decision		12 (4·5%)	21 (7·8%)
	Intake of other antimalarial drugs		2 (0·7%)	0
	Intake of antibiotics with antimalarial activity		2 (0·7%)	2 (0·7%)
	Investigator's decision		1 (0·4%)	0
	Lost to follow-up		25 (9·3%)	24 (8·9%)
	Other reason		2 (0·7%)	6 (2·2%)

Data are n (%).

^*Percentage values indicate proportion of withdrawals.